Sec. 21a-317. (Formerly Sec. 19-504 l ). Registration required. Notification of transportation of a controlled substance to treat a patient at an alternate location required. Report of dispensation of a controlled substance at an alternate location required.
257 words·~1 min read·
/ct/title-21a/chapter-420c-controlled-substance-registration/21a-317·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Every practitioner who distributes, administers or dispenses any controlled substance or who proposes to engage in distributing, prescribing, administering or dispensing any controlled substance within this state shall
(1)obtain a certificate of registration issued by the Commissioner of Consumer Protection in accordance with the provisions of this chapter,
(2)if the practitioner is engaged in prescribing a controlled substance, register for access to the electronic prescription drug monitoring program established pursuant to subsection
(j)of section 21a-254 in a manner prescribed by the commissioner, and
(3)if the practitioner is engaged in transporting a controlled substance for the purpose of treating a patient in a location that is different than the address that the practitioner provided to the Department of Consumer Protection as a registrant, as defined in section 21a-240 , notify the department, in a manner prescribed by the commissioner, of the intent to transport such controlled substance and, after dispensing such controlled substance, return any remaining amount of such controlled substance to a secure location at the address provided to the department. If the practitioner cannot return any remaining amount of such controlled substance to such address, the commissioner may approve an alternate location, provided such location is also approved by the federal Drug Enforcement Agency, or any successor agency. The practitioner shall report any dispensation by the practitioner of a controlled substance that occurs at a location other than the address provided to the department to the prescription drug monitoring program pursuant to subsection
(j)of section 21a-254 upon returning to such address.